These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 38419787)

  • 21. Consistent effects of empagliflozin on cardiovascular and kidney outcomes irrespective of diabetic kidney disease categories: Insights from the EMPA-REG OUTCOME trial.
    Wanner C; Inzucchi SE; Zinman B; Koitka-Weber A; Mattheus M; George JT; von Eynatten M; Hauske SJ;
    Diabetes Obes Metab; 2020 Dec; 22(12):2335-2347. PubMed ID: 32744354
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Analysis from the EMPA-REG OUTCOME
    Mayer GJ; Wanner C; Weir MR; Inzucchi SE; Koitka-Weber A; Hantel S; von Eynatten M; Zinman B; Cherney DZI
    Kidney Int; 2019 Aug; 96(2):489-504. PubMed ID: 31142441
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial.
    Heerspink HJL; Sattar N; Pavo I; Haupt A; Duffin KL; Yang Z; Wiese RJ; Tuttle KR; Cherney DZI
    Lancet Diabetes Endocrinol; 2022 Nov; 10(11):774-785. PubMed ID: 36152639
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial.
    Verma S; Mazer CD; Yan AT; Mason T; Garg V; Teoh H; Zuo F; Quan A; Farkouh ME; Fitchett DH; Goodman SG; Goldenberg RM; Al-Omran M; Gilbert RE; Bhatt DL; Leiter LA; Jüni P; Zinman B; Connelly KA
    Circulation; 2019 Nov; 140(21):1693-1702. PubMed ID: 31434508
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Empagliflozin in Patients with Chronic Kidney Disease.
    ; Herrington WG; Staplin N; Wanner C; Green JB; Hauske SJ; Emberson JR; Preiss D; Judge P; Mayne KJ; Ng SYA; Sammons E; Zhu D; Hill M; Stevens W; Wallendszus K; Brenner S; Cheung AK; Liu ZH; Li J; Hooi LS; Liu W; Kadowaki T; Nangaku M; Levin A; Cherney D; Maggioni AP; Pontremoli R; Deo R; Goto S; Rossello X; Tuttle KR; Steubl D; Petrini M; Massey D; Eilbracht J; Brueckmann M; Landray MJ; Baigent C; Haynes R
    N Engl J Med; 2023 Jan; 388(2):117-127. PubMed ID: 36331190
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Can we go beyond surrogates?
    Drexler A
    J Diabetes; 2017 Nov; 9(11):976-977. PubMed ID: 28692750
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights From EMPEROR-Reduced.
    Zannad F; Ferreira JP; Pocock SJ; Zeller C; Anker SD; Butler J; Filippatos G; Hauske SJ; Brueckmann M; Pfarr E; Schnee J; Wanner C; Packer M
    Circulation; 2021 Jan; 143(4):310-321. PubMed ID: 33095032
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cardio/Kidney Composite End Points: A Post Hoc Analysis of the EMPA-REG OUTCOME Trial.
    Ferreira JP; Kraus BJ; Zwiener I; Lauer S; Zinman B; Fitchett DH; Koitka-Weber A; George JT; Ofstad AP; Wanner C; Zannad F
    J Am Heart Assoc; 2021 Apr; 10(7):e020053. PubMed ID: 33754809
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Impact of Empagliflozin on Obstructive Sleep Apnea and Cardiovascular and Renal Outcomes: An Exploratory Analysis of the EMPA-REG OUTCOME Trial.
    Neeland IJ; Eliasson B; Kasai T; Marx N; Zinman B; Inzucchi SE; Wanner C; Zwiener I; Wojeck BS; Yaggi HK; Johansen OE;
    Diabetes Care; 2020 Dec; 43(12):3007-3015. PubMed ID: 33004464
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cardiac and kidney benefits of empagliflozin in heart failure across the spectrum of kidney function: Insights from the EMPEROR-Preserved trial.
    Sharma A; Ferreira JP; Zannad F; Pocock SJ; Filippatos G; Pfarr E; Petrini M; Kraus BJ; Wanner C; Packer M; Butler J; Anker SD
    Eur J Heart Fail; 2023 Aug; 25(8):1337-1348. PubMed ID: 37062851
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial.
    Heerspink HJL; Jongs N; Chertow GM; Langkilde AM; McMurray JJV; Correa-Rotter R; Rossing P; Sjöström CD; Stefansson BV; Toto RD; Wheeler DC; Greene T;
    Lancet Diabetes Endocrinol; 2021 Nov; 9(11):743-754. PubMed ID: 34619108
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
    Zinman B; Wanner C; Lachin JM; Fitchett D; Bluhmki E; Hantel S; Mattheus M; Devins T; Johansen OE; Woerle HJ; Broedl UC; Inzucchi SE;
    N Engl J Med; 2015 Nov; 373(22):2117-28. PubMed ID: 26378978
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Metabolic syndrome in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a post hoc analyses of the EMPA-REG OUTCOME trial.
    Ferreira JP; Verma S; Fitchett D; Ofstad AP; Lauer S; Zwiener I; George J; Wanner C; Zinman B; Inzucchi SE
    Cardiovasc Diabetol; 2020 Nov; 19(1):200. PubMed ID: 33243221
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rationale and design of a multicenter placebo-controlled double-blind randomized trial to evaluate the effect of empagliflozin on endothelial function: the EMBLEM trial.
    Tanaka A; Shimabukuro M; Okada Y; Taguchi I; Yamaoka-Tojo M; Tomiyama H; Teragawa H; Sugiyama S; Yoshida H; Sato Y; Kawaguchi A; Ikehara Y; Machii N; Maruhashi T; Shima KR; Takamura T; Matsuzawa Y; Kimura K; Sakuma M; Oyama JI; Inoue T; Higashi Y; Ueda S; Node K;
    Cardiovasc Diabetol; 2017 Apr; 16(1):48. PubMed ID: 28403850
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of polyvascular disease with and without co-existent kidney dysfunction on cardiovascular outcomes in diabetes: A post hoc analysis of EMPA-REG OUTCOME.
    Verma S; Mazer CD; Inzucchi SE; Wanner C; Ofstad AP; Johansen OE; Zwiener I; George JT; Butler J; Zinman B
    Diabetes Obes Metab; 2021 May; 23(5):1173-1181. PubMed ID: 33502090
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effect of empagliflozin on the total burden of cardiovascular and hospitalization events in the Asian and non-Asian populations of the EMPA-REG OUTCOME trial of patients with type 2 diabetes and cardiovascular disease.
    Kaku K; Wanner C; Anker SD; Pocock S; Yasui A; Mattheus M; Lund SS
    Diabetes Obes Metab; 2022 Apr; 24(4):662-674. PubMed ID: 34908223
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Empagliflozin lowers serum uric acid in chronic kidney disease: exploratory analyses from the EMPA-KIDNEY trial.
    Mayne KJ; Sardell RJ; Staplin N; Judge PK; Zhu D; Sammons E; Cherney DZI; Green JB; Levin A; Pontremoli R; Hauske SJ; Emberson J; Preiss D; Landray MJ; Baigent C; Wanner C; Haynes R; Herrington WG;
    Nephrol Dial Transplant; 2024 Sep; ():. PubMed ID: 39277784
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of Qualifying Atherosclerotic Cardiovascular Disease Diagnosis Proximity on Cardiovascular Risk and Benefit of Empagliflozin in the EMPA-REG OUTCOME Trial.
    Odutayo A; Zinman B; Wanner C; Zwiener I; Lund SS; Hantel S; Fitchett D; Udell JA;
    CJC Open; 2024 Jul; 6(7):868-875. PubMed ID: 39026628
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-effectiveness of empagliflozin versus canagliflozin, dapagliflozin, or standard of care in patients with type 2 diabetes and established cardiovascular disease.
    Reifsnider OS; Kansal AR; Gandhi PK; Cragin L; Brand SB; Pfarr E; Fahrbach K; Ustyugova A
    BMJ Open Diabetes Res Care; 2021 May; 9(1):. PubMed ID: 33941549
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.